vimarsana.com

Page 22 - Advanced Accelerator Applications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Olaparib regimen benefits men with metastatic castration-resistant prostate cancer

SAN FRANCISCO  — The addition of olaparib to abiraterone acetate significantly extended radiographic PFS as first-line treatment for metastatic castration-resistant prostate cancer, according to an interim analysis of the randomized phase 3 PROpel study. The findings, presented at ASCO Genitourinary Cancers Symposium, showed men experienced the benefit regardless of homologous

Radiopharmaceuticals Market size is Expected to Reach US$ 6107 2 Billion in 2031| Exhibit a CAGR of 4 90%

Radiopharmaceuticals Market size is Expected to Reach US$ 6107 2 Billion in 2031| Exhibit a CAGR of 4 90%
fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.